Cabot Global Stocks Explorer 696
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
alternative investments
Read More
alternative investments Archives
Cabot Global Stocks Explorer test
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Cabot Global Stocks Explorer 695
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Cabot Dividend Investor 919
Profit from the American Energy Export Boom
One of the constants in life is change. The winds of change seem to swoop in and disrupt things we mistakenly consider permanent. Understanding exactly when and where such events occur is crucial to successful investing.
One such change...
Read More
Cabot Global Stocks Explorer 694
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
One of our portfolio stocks moves is being retired and there is news on five more.
Read More
Cabot Global Stocks Explorer 693
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
One of our portfolio stocks moves from Strong Buy to Hold.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Three retail stocks reported earnings.
Read More
Cabot Dividend Investor 819
Defense is the Best Offer
Here we are in the tenth year of an economic recovery and bull market. All recoveries end in recession and all bull markets end in bear markets. Both have already well exceeded the average historical life spans. In fact, is...
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
A Spanish news outlet, Intereconomia.com, is reporting that biotech company Amgen (AMGN) is in talks to buy Alexion Pharmaceuticals (ALXN) for close to $200 per share.
Read More
Cabot Global Stocks Explorer 692
Our Emerging Markets Timer as found support in recent weeks, but that hasn’t been enough to produce a new buy signal.
Read More
Cabot Undervalued Stocks Advisor Special Bulletin
Four stocks in our portfolios reported earnings this week.
Read More
Cabot Global Stocks Explorer 691
Emerging markets (EEM) moved more solidly into bullish territory this week moving ahead of both its 20-day and 50-day moving averages.
Read More
Cabot Dividend Investor 719
The Dog Days of Summer
We are in the dog days of summer, the hottest, most sultry days of the year. The expression “dog days” is an old one. In fact, it’s really old. The Romans used it.
It’s one of those expressions that everyone but...
Read More
Cabot Global Stocks Explorer 690
Emerging markets (EEM) moved more solidly into bullish territory this week moving ahead of both its 20-day and 50-day moving averages.
Read More
Cabot Global Stocks Explorer 689
Emerging markets (EEM) moved more solidly into bullish territory this week moving ahead of both its 20-day and 50-day moving averages.
Read More
Cabot Emerging Markets Investor 688
Our Emerging Markets Timer is still solidly in the bull camp, with the recent pullback being modest compared to the year-to-date upmove.
Read More
Cabot Emerging Markets Investor 687
Our Emerging Markets Timer is still solidly in the bull camp, with the recent pullback being modest compared to the year-to-date upmove.
Read More
Cabot Emerging Markets Investor 686
Our Emerging Markets Timer is still solidly in the bull camp, with the recent pullback being modest compared to the year-to-date upmove.
Read More
Enter Your Log In Credentials
- Lost your password? Create New Password
- No account? Sign up